TON - January 2017, Vol 10, No 1

The findings of 2 separate studies presented at the recent European Society for Medical Oncology (ESMO) Congress suggest that oncology nurses need more education and training on how to manage adverse effects from cancer and its treatment.
Adult hospice and palliative care patients with hyperactive delirium symptoms who were given risperidone or haloperidol had greater delirium symptoms at 72 hours than those given placebo.
Advance care planning (ACP) continues to be a vital part of comprehensive, patient-centered cancer care, but barriers to uptake and implementation remain.
Parents with inherited cancer mutations often wonder when to disclose results to their children and what affect it will have on them.
Although patient self-reporting of symptoms has been shown to improve longitudinal tracking of symptoms and increase patient engagement in their care, these assessment tools are often underutilized in clinical care.
Adherence to infusional or injectable anticancer drugs is not problematic—as long as the patient gets the infusion or injection, adherence is assured—but adherence is an emergent problem with newer oral anticancer drugs.
On December 19, 2016, the FDA granted accelerated approval to rucaparib (Rubraca; Clovis Oncology Inc), a poly ADP-ribose polymerase inhibitor, for the treatment of patients with advanced ovarian cancer whose tumors have deleterious BRCA gene mutation, and who have been treated with ≥2 chemotherapies.
Lori Williams, PhD, RN, has worked in oncology nursing for more than 30 years, and focuses her research on symptoms of cancer and cancer treatment.
Prophylactic probiotics can potentially prevent radiation enteropathy, according to research presented by Matthew A. Ciorba, MD.
A persistent medi­­cation safety issue is getting the attention it has long deserved.
Page 2 of 3
Results 11 - 20 of 22